0 Replies
WORCESTER, Mass., Jan 27, 2011 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, Inc., positive data were generated demonstrating that RXi’s sd-rxRNA™ technology can be used, in vitro, to specifically enhance the activity... Contine Reading & Discuss→
0 Replies
Stories include:
Genetically modified viruses engineered to destroy cancer cells might be more effective in treating deadly brain tumors if equipped with an enzyme that helps them penetrate the tumor. Report
The global market for drug-eluting stents is expected to reach $6 billion by 2015, according to a new report.... Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - January 18, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) ("the Company") today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Calando debt to Arrowhead into equity. Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - January 18, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a publicly-traded, Seoul, Korea-based electronics company (KOSDAQ: 040670). Contine Reading & Discuss→
0 Replies
BOULDER, Colo., January 18, 2011 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that it is the recipient of the University of Colorado (CU) Technology Transfer Office Bioscience Company of the Year award. ... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Jan. 6, 2011 /PRNewswire/ — Generex Biotechnology Corporation (http://www.generex.com/) (OTC Bulletin Board: GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (http://www.antigenexpress.com/), and RXi Pharmaceuticals Corporation (http://www.rxipharma.com/) (NasdaqCM: RXII), a recognized leader in RNAi-based therapeutics, today announced that they have obtained positive early research data from... Contine Reading & Discuss→
0 Replies
PfizerallianceFINALrelease.01.04.11.pdf
Pfizer to make payment of $14 million for access to Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform to develop RNA-targeted drugs
Santaris Pharma A/S eligible to receive milestone payments of up to $600 million as well as royalties on sales of products that may develop... Contine Reading & Discuss→
